The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Protagonist Therapeutics Inc shares valued at $570,300 were sold by MOLINA ARTURO MD on Jun 10 ’25. At $57.03 per share, MOLINA ARTURO MD sold 10,000 shares. The insider’s holdings dropped to 83,892 shares worth approximately $4.72 million following the completion of this transaction.
Also, MOLINA ARTURO MD sold 10,000 shares, netting a total of over 555,100 in proceeds. Following the sale of shares at $55.51 each, the insider now holds 83,892 shares.
Before that, ARTURO MOLINA had added 10,000 shares to its account. In a trade valued at $570,269, the Officer bought Protagonist Therapeutics Inc shares for $57.03 each.
As published in their initiating research note from Goldman on December 06, 2024, Protagonist Therapeutics Inc [PTGX] has been a Neutral and the price target has been revised to $47. Analysts at BMO Capital Markets started covering the stock with ‘”an Outperform”‘ outlook in a report released in early December. As of November 05, 2024, Wedbush has initiated its “an Outperform” rating for PTGX. Earlier on September 24, 2024, TD Cowen initiated its rating. Their recommendation was “a Buy” for PTGX stock.
Analyzing PTGX Stock Performance
On last trading session,, Protagonist Therapeutics Inc [NASDAQ: PTGX] rose 1.77% to $56.32. The stock’s lowest price that day was $54.475, but it reached a high of $56.675 in the same session. During the last five days, there has been a surge of approximately 4.65%. Over the course of the year, Protagonist Therapeutics Inc shares have jumped approximately 45.91%.
Support And Resistance Levels for Protagonist Therapeutics Inc (PTGX)
RSI (Relative Strength Index) is 75.01 on the 14-day chart, showing overbought technical sentiment.
Is Protagonist Therapeutics Inc subject to short interest?
Stocks of Protagonist Therapeutics Inc saw a sharp steep in short interest on 2025-05-30 dropping by -0.91 million shares to 5.21 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 6.12 million shares. A decline of -17.41% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.59 of the overall float, the days-to-cover ratio (short ratio) decline to 6.59.
